SCHEMBL6185834

SCHEMBL6185834

CCN(Cc1cccc(-c2ccc(C=O)cc2)c1)C(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 3/20 0.58
HPGD P15428 4/20 0.57
ALDH1A1 P00352 2/20 0.57
MAPT P10636 1/20 0.57
BCHE P06276 1/20 0.56
PPARG P37231 1/20 0.55
TSHR P16473 2/20 0.50
GAA P10253 1/20 0.50
LMNA P02545 1/20 0.50
PTGES O14684 1/20 0.49
HDAC1 Q13547 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
BCL2 P10415 1/20 0.47
HSD17B1 P14061 1/20 0.46
HSD17B2 P37059 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MAPK1 P28482 1/20 0.45
TRIM24 O15164 1/20 0.45
TRIM33 Q9UPN9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6184104 0.92 BCHE (0.53) AOC3HPGDALDH1A1MAPTBCHE
SCHEMBL6186288 0.89 HPGD (0.56) AOC3HPGDALDH1A1MAPTBCHE
SCHEMBL6184553 0.88 PTGES (0.52) AOC3HPGDALDH1A1MAPTBCHE
SCHEMBL6182236 0.88 HSD17B2 (0.62) AOC3BCHEHSD17B1HSD17B2KMT2A
SCHEMBL7556594 0.83 PPARG (0.59) AOC3HPGDALDH1A1MAPTBCHE
SCHEMBL6183616 0.82 PTPN1 (0.50) AOC3HPGDBCHEKMT2A
SCHEMBL6183613 0.82 PTPN1 (0.50) AOC3HPGDBCHEKMT2A
SCHEMBL6478817 0.80 PPARG (0.56) AOC3HPGDALDH1A1MAPTBCHE
SCHEMBL6472820 0.80 AOC3 (0.49) AOC3HPGDBCHETSHRLMNA
SCHEMBL6184987 0.79 AOC3 (0.52) AOC3HPGDALDH1A1MAPTBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed
CN-1468226-A Biphenyl derivatives and their use as ppar-gamma receptor activators �������о�����չ˽�����޹�˾ 2004-01-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD AOC3 1747/4885HPGD 492/4885ALDH1A1 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.